Siegfried Holding AG
SFZN
Rangering i aksjer
#4105
Siegfried Holding AG, together with its subsidiaries, engages in contract... Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Aksjekurs
$88.34
Markedsverdi
$3.87B
Endring (1 dag)
1.68%
Endring (1 år)
-12.97%
Land
CH
Handel Siegfried Holding AG (SFZN)
Kategori
Healthcare
Inntekter for Siegfried Holding AG (SFZN)
Inntekter i 2026 TTM: 0
Ifølge Siegfried Holding AG sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Siegfried Holding AG fra 2002 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | $262.95M | 21.02% |
| 2024 | $217.28M | 21.51% |
| 2023 | $178.81M | -24.44% |
| 2022 | $236.63M | 70.46% |
| 2021 | $138.82M | 68.39% |
| 2020 | $82.44M | 54.98% |
| 2019 | $53.19M | -25.42% |
| 2018 | $71.32M | 20.14% |
| 2017 | $59.37M | 73.97% |
| 2016 | $34.13M | -7.94% |
| 2015 | $37.07M | 15.84% |
| 2014 | $32.00M | -43.19% |
| 2013 | $56.32M | 239.87% |
| 2012 | $16.57M | 48.10% |
| 2011 | $11.19M | -312.32% |
| 2010 | $-5.27M | -86.49% |
| 2009 | $-39.02M | -52.71% |
| 2008 | $-82.51M | -453.96% |
| 2007 | $23.31M | 6.35% |
| 2006 | $21.92M | -32.38% |
| 2005 | $32.41M | 96.31% |
| 2004 | $16.51M | -65.51% |
| 2003 | $47.87M | -4.28% |
| 2002 | $50.01M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
